drugset
drugset / Trial / NCT05690646

Prophylactic Effect of Nirmatrelvir/Ritonavir and Ursodeoxycholic Acid on Reducing Complications After Cardiac Surgery

NCT05690646 ↗

Phase 4 Unknown 491 enrolled China National Center for Cardiovascular Diseases
RandomizedParallel-groupOpen-labelPrevention

Summary

Prophylactic effect of nirmatrelvir/ritonavir and ursodeoxycholic acid on reducing complications after cardiac surgery during covid-19 pandemics (the pep trial) is a multicenter, randomized controlled trial. The aim of the pep trial is to investigate whether prophylactic use of nirmatrelvir/ritonavir and ursodeoxycholic could reduce complications after cardiac surgery.

Timeline

Start
2023-01-28
Primary completion
2023-03-24
Completion
2026-01-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Nirmatrelvir Small molecule 300 mg —
Subject Ritonavir Other / unclassified 100 mg —
Subject Ursodeoxycholic Acid Small molecule 15 mg/kg —

Indications

No indication recorded.